A 62-year-old man with newly diagnosed atrial fibrillation (AF) and a CHA₂DS₂-VASc score of 3 presents for anticoagulation counselling. Regarding anticoagulant choice and AF management, all of the following are true EXCEPT:

Explanation

## Anticoagulation Strategy in Atrial Fibrillation ### Correct Statements (Options 0, 2, 3) **Key Point:** Direct oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban) are non-inferior or superior to warfarin for stroke prevention in non-valvular AF and are preferred first-line agents due to predictable pharmacokinetics, no monitoring requirement, and lower risk of intracranial bleeding. Warfarin remains appropriate if DOACs are contraindicated (severe renal impairment, mechanical mitral valve) [cite:Harrison 21e Ch 226]. **Clinical Pearl:** Left atrial appendage occlusion (via percutaneous device such as WATCHMAN or Amulet) is a Class IIb recommendation for patients with absolute contraindications to anticoagulation (e.g., recurrent major bleeding, thrombocytopenia) or those with recurrent thromboembolic events despite therapeutic anticoagulation [cite:ESC AF Guidelines 2019]. **High-Yield:** In haemodynamically unstable AF with rapid ventricular response causing hypotension, syncope, or acute heart failure, immediate DC cardioversion is indicated as a life-saving intervention. Anticoagulation status should not delay cardioversion in acute haemodynamic compromise; anticoagulation is initiated concurrently or immediately post-cardioversion [cite:Harrison 21e Ch 226]. ### Why Option 1 is INCORRECT **Warning:** Aspirin monotherapy is NOT an acceptable alternative to anticoagulation in patients with a CHA₂DS₂-VASc score of 3 (moderate-to-high stroke risk). **High-Yield:** Aspirin is inferior to anticoagulation for stroke prevention in AF: - Aspirin reduces stroke risk by ~20%, whereas anticoagulation reduces risk by ~65–70% - Aspirin is only considered in patients with CHA₂DS₂-VASc score of 0 (male) or 1 (female) who refuse anticoagulation - A score of 3 mandates anticoagulation; if the patient refuses oral anticoagulants, LAA occlusion or parenteral anticoagulation (e.g., LMWH bridge) should be discussed [cite:ESC AF Guidelines 2019]. ### Anticoagulation Decision Algorithm in AF ```mermaid flowchart TD A[AF diagnosis]:::outcome --> B{CHA₂DS₂-VASc score}:::decision B -->|Score 0 male or 1 female| C[No anticoagulation or aspirin]:::action B -->|Score ≥1 male or ≥2 female| D[Anticoagulation indicated]:::action D --> E{DOAC suitable?}:::decision E -->|Yes| F[DOAC first-line]:::action E -->|No: severe renal impairment or mechanical valve| G[Warfarin]:::action E -->|Refuses anticoagulation| H[Discuss LAA occlusion]:::action F --> I[Monitor renal function annually]:::action G --> J[Target INR 2–3]:::action ``` ### Comparison: Anticoagulation Options in AF | Anticoagulant | Indication | Advantage | Limitation | | --- | --- | --- | --- | | DOAC (apixaban, dabigatran, edoxaban, rivaroxaban) | CHA₂DS₂-VASc ≥1 (male) or ≥2 (female) | Predictable PK, no monitoring, lower ICH risk | Renal clearance, cost, adherence | | Warfarin | CHA₂DS₂-VASc ≥1 (male) or ≥2 (female); mechanical valve | Reversible, long track record | INR monitoring, drug interactions, dietary factors | | Aspirin | CHA₂DS₂-VASc 0 (male) or 1 (female) only | Tolerability | Inferior efficacy (~20% risk reduction) | | LAA occlusion | Contraindication to anticoagulation; recurrent VTE despite anticoagulation | Eliminates need for long-term anticoagulation | Procedural risk, device-related thrombosis |